98%
921
2 minutes
20
Background: Laparoscopic cholecystectomy (LC) to treat mild biliary acute pancreatitis (MBAP) during index admission is recommended. However, the optimal surgical timing is controversial, considering that patients are actually often discharged from hospital and readmitted for elective cholecystectomy. Moreover, previous studies showed an uneven patients' stratification for pancreatitis severity. The aim of this study was to determine the outcome of patients homogenously categorizedfor MBAP according to the newest pancreatitis classifications, undergoing cholecystectomy with different timing.
Methods: We retrospectively identified all patients undergoing cholecystectomy from 2008 to 2015 for MBAP, according to the 2012 Revision of the Atlanta Classification and the Determinant-Based Classification of Acute Pancreatitis, and stratified them in two groups: index cholecystectomy (IC) and interval-delayed cholecystectomy (IDC, after at least 4 weeks).
Results: One hundred and three patients were analyzed. IC was performed in 40 patients (38.8%) while IDC in 63 patients (61.2%). The two groups were similar in comorbidities and pancreatitis severity at admission. There were no differences for conversion rate, operation length, total length of hospitalization and overall complication rates. However, IDC patients had a 33.3% rate of re-hospitalization for recurrent biliary-pancreatic events while waiting for the elective procedure and showed a higher rate of acute cholecystitis at histological diagnosis than IC (11.1% vs. 0%, P=0.041).
Conclusions: Among patients affected by MBAP, homogenously assessed following the new acute pancreatitis severity scores, the performance of cholecystectomy during the index admission is the best treatment option in order to avoid further undesired hospitalizations for recurrent biliary/pancreatic events while waiting for surgery.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.23736/S0026-4733.17.07356-4 | DOI Listing |
Int J Biol Macromol
September 2025
Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Pancreatology
August 2025
Department of Dermatology, The People's Hospital of Rongchang District, Chongqing, China. Electronic address:
Gastrointest Endosc
September 2025
Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Electronic address:
BMJ Open Gastroenterol
September 2025
Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, Noord-Holland, The Netherlands
Objective: Patients with acute pancreatitis show reduced gut microbiome diversity and high abundance of pathogenic bacteria compared with healthy subjects. Admission microbiome profiles are increasingly linked to severity, but methodology and study quality hamper interpretation. Our aim was to investigate whether admission microbiome analysis provides robust and reproducible associations with severity and complications of acute pancreatitis.
View Article and Find Full Text PDFJ Ethnopharmacol
September 2025
Department of Emergency Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China. Electronic address:
Ethnopharmacological Relevance: Liquorice (Gancao), a classic Chinese herb, has been historically prescribed for inflammation and gastrointestinal disorders. Its bioactive flavonoid liquiritigenin (4',7-dihydroxyflavone) exhibits anti-inflammatory properties, yet its efficacy against acute pancreatitis (AP) remains unexplored.
Aim: To systematically investigate the therapeutic potential of liquiritigenin against AP and decipher its estrogen receptor beta (ERβ)-mediated mitochondrial regulatory mechanisms.